Cerity Partners’s Ginkgo Bioworks DNA Stock Holding History

Cerity Partners’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$108K	Buy	+10,906	New	+$91.2K	﹤0.01%	3204
2024 Q3	–	Sell	-6,520	Closed	-$87.2K	–	2557
2024 Q2	$87.2K	Sell	6,520 -109	-2%	-$3.25K	﹤0.01%	2125
2024 Q1	$308K	Buy	6,629 +1,389	+27%	+$71.9K	﹤0.01%	1854
2023 Q4	$354K	Buy	5,240 +261	+5%	+$16K	﹤0.01%	1433
2023 Q3	$360K	Buy	4,979 +4,648	+1,404%	+$372K	﹤0.01%	1087
2023 Q2	$24.6K	Sell	331 -49	-13%	-$2.9K	﹤0.01%	1598
2023 Q1	$20.2K	Buy	380 +21	+6%	+$1.33K	﹤0.01%	1824
2022 Q4	$24.3K	Buy	359 +35	+11%	+$3.22K	﹤0.01%	1456
2022 Q3	$40K	Buy	+324	New	+$38.6K	﹤0.01%	1141

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Cerity Partners's DNA Position: Q2 2026 in Review

Cerity Partners opened a new position in Ginkgo Bioworks (DNA) in Q2 2026: 10,906 shares worth $108K. The stake represents ﹤0.01% of the portfolio and ranks #3204 among its holdings. This is a return to the name: Cerity Partners previously reported a position in DNA as recently as Q2 2024.

Cerity Partners first reported a position in DNA in Q3 2022 and has held it in 9 quarters since. The position peaked at $360K in Q3 2023. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Cerity Partners held 10,906 shares of Ginkgo Bioworks worth $108K as of Q2 2026.
Ginkgo Bioworks was a new Cerity Partners position in Q2 2026.
Ginkgo Bioworks made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3204 holding.
Cerity Partners first reported a position in Ginkgo Bioworks in Q3 2022 and has held it in 9 quarters since.
Cerity Partners's Ginkgo Bioworks position peaked at $360K in Q3 2023.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.